IMV Inc. (IMV): Price and Financial Metrics

IMV Inc. (IMV): $0.82

0.02 (-2.55%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add IMV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#269 of 381

in industry

IMV Price/Volume Stats

Current price $0.82 52-week high $12.70
Prev. close $0.84 52-week low $0.48
Day low $0.78 Volume 44,800
Day high $0.84 Avg. volume 233,607
50-day MA $0.64 Dividend yield N/A
200-day MA $3.23 Market Cap 9.63M

IMV Stock Price Chart Interactive Chart >


IMV Inc. (IMV) Company Bio


IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.


IMV Latest News Stream


Event/Time News Detail
Loading, please wait...

IMV Latest Social Stream


Loading social stream, please wait...

View Full IMV Social Stream

Latest IMV News From Around the Web

Below are the latest news stories about IMV INC that investors may wish to consider to help them evaluate IMV as an investment opportunity.

IMV Receives NASDAQ Delisting Notice

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 08, 2023--IMV Inc. (the "Company" or "IMV") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exerci

Yahoo | May 8, 2023

Horizon Technology Finance Announces First Quarter 2023 Financial Results

Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the first quarter ended March 31, 2023.

Yahoo | May 2, 2023

IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 01, 2023--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act

Yahoo | May 1, 2023

IIROC Trading Halt - IMV

The following issues have been halted by IIROC:

Yahoo | May 1, 2023

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 31, 2023--IMV Inc. ("IMV" or the "Company") (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company’s

Yahoo | March 31, 2023

Read More 'IMV' Stories Here

IMV Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -9.89%
3-year -97.05%
5-year -97.22%
YTD N/A
2023 0.00%
2022 -80.08%
2021 -60.39%
2020 6.21%
2019 -43.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!